Although the HHS proposal to eliminate rebates is aimed at reducing seniors’ cost sharing by lowering list prices for branded drugs, the proposed rule also could solve the so-called rebate trap that has thwarted biosimilars competition, Association for Accessible Medicines President and CEO Chip Davis said. However, Davis also worries that brands might find a way to use up-front discounts to game formularies, so he would like the government to require that insurers and pharmacy benefit managers place biosimilars and...